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Seroepidemiologic studies of Pneumocystis pneumo-
nia (PCP) in humans have been limited by inadequate
reagents. We have developed an enzyme-linked
immunosorbent assay (ELISA) using three overlapping
recombinant fragments of the human Pneumocystis major
surface glycoprotein (MsgA, MsgB, and MsgC) for analysis
of antibody responses in HIV-positive patients and healthy
blood donors. HIV-positive patients had significantly higher
antibody levels to all Msg fragments. Furthermore, HIV-
positive patients who experienced a previous episode of
PCP (PCP-positive) had higher levels of antibodies to
MsgC than patients who never had PCP. A significant asso-
ciation was found between ELISA antibody level and reac-
tivity by Western blot in HIV-positive patients, especially
those who were PCP-positive. Thus, this ELISAwill be use-
ful in studying serum antibody responses to Pneumocystis
in different human populations. 
P
neumocystis is an opportunistic fungus of worldwide
distribution that can cause lethal pneumonia in persons
infected with HIV and in other persons with depressed
immune function (1). Pneumocystis also infects a variety
of animals and causes pneumonia in those that are immun-
odeficient or immunosuppressed (2). Since Pneumocystis
organisms in humans and animals are very similar, and the
pneumonia that develops has many common features,
these microbes were originally thought to belong to a sin-
gle genus and species. However, data over the past decade
have shown that Pneumocystis is genetically diverse and
host-specific, suggesting that studies of immune responses
to Pneumocystis are best performed by using organisms or
organism products that are specific for that host (1).
Pneumocystis nomenclature, which is evolving and some-
what controversial, has designated two species so far:
P. carinii for rat-derived organisms and P. jiroveci for
human-derived organisms (3). 
Seroepidemiologic surveys have shown that exposure
to Pneumocystis occurs early in life; by 2 to 4 years of age,
most children have antibodies to the organism (4–8). Since
a reliable in vitro culture system for Pneumocystis has not
been developed, antigens used in these studies consisted
mainly of whole or fractionated organism preparations
derived from infected human or rodent lungs. The use of
human  Pneumocystis has been further hindered by the
small amounts of material that can be obtained from clini-
cal specimens. Serologic surveys using crude
Pneumocystis antigen preparations are generally not effec-
tive as clinical or epidemiologic tools. The frequency or
level of serum antibodies to Pneumocystis among HIV-
positive patients and other immunocompromised hosts has
usually been similar to the corresponding value in healthy
controls (6,8–15). Conflicting results have been obtained
in attempts to distinguish past from present infection or
colonization from active disease (16–21). Thus, no stan-
dardized antigen preparations are available for antigen-
specific immunologic studies of Pneumocystis infection in
humans. 
The Pneumocystis antigen that has received the most
attention is the 95- to 140-kDa major surface glycoprotein
(Msg or gpA), which contains shared and species-specific
epitopes, elicits humoral and cellular protective immune
responses, and plays a central role in the interaction of
Pneumocystis with its host (2–8,22). However, native P.
jiroveci Msg is in short supply and contains multiple iso-
forms of this glycoprotein, which complicates immunolog-
ic studies of this antigen (23,24). 
Recombinant  Pneumocystis antigens offer a viable
approach to developing novel reagents for use in immuno-
logic assays (25–27). One group of investigators has
developed two recombinant fragments that correspond to
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blot analysis, the carboxyl fragment was recognized more
frequently by serum specimens than the amino fragment
but did not distinguish between HIV-positive patients and
healthy donors. An enzyme-linked immunosorbent assay
(ELISA) using the carboxyl fragment showed significant-
ly higher antibody levels in HIV-negative patients with
Pneumocystis  pneumonia (PCP) compared with healthy
controls, but it could not distinguish among HIVpositive,
PCP-positive and HIV-positive, PCP-negative patients and
controls. 
We recently developed three overlapping recombinant
fragments of Msg that span the length of P. jiroveci Msg
and used these antigens to measure serum antibodies by
Western blot in healthy blood donors and HIV patients
(27). The data showed significant differences in the fre-
quency of reactivity to the Msg constructs, not only
between the two groups but also between PCP-positive and
PCP-negative patients with HIV.
Although Western blot is a valuable serologic tech-
nique, its major limitation is that it is not quantitative.
ELISA overcomes this problem and is better suited for
population surveys. We developed an ELISAusing recom-
binant Msg fragments as antigens and analyzed antibody
responses of healthy blood donors and HIV-positive
patients (including PCP-positive and PCP-negative
patients). We present three different analyses of the ELISA
data and compare the results to those obtained by Western
blot.
Materials and Methods
Serum samples as well as the demographic and clinical
information about the human participants in this study
were described in detail in our earlier report (27). That
report also describes how recombinant Msg fragments
were cloned, expressed, and purified and how Western blot
was performed.
Enzyme-linked Immunosorbent Assay
Serum specimens were tested against the following
antigens: recombinant Msg fragments; Escherichia coli
extract expressing the pET vector without insert as a vec-
tor control; tetanus toxoid (TT) as a positive control; phos-
phate-buffered saline (PBS) without antigen (negative
control). Astandard serum sample, obtained from a healthy
donor with known reactivity to MsgA, MsgB, and MsgC in
Western blot, is run on each plate as a control. Duplicate
wells of a 96-well plate were coated with antigen
(1  µg/mL, 100 µL/well in PBS pH 7.4 overnight. The
plates were washed in wash buffer (PBS with 0.05%
Tween-20) and blocked with blocking buffer (wash buffer
with 5% nonfat milk) (200 µL/well) for 2 h at room tem-
perature. The plates were washed again, and human serum
diluted 1/100 in blocking buffer was added to each well
(100 µL/well). The plates were rocked overnight at 4°C,
washed in wash buffer, and horseradish peroxidase (HRP)-
labeled goat anti-human immunoglobulin (Ig) G (heavy
and light chains) was added to each well (100 µL/well at
1/5,000 dilution in blocking buffer). HRP-labeled S-pro-
tein was used on each plate as a positive control and to cor-
rect for antigen loading. The plates were incubated at room
temperature for 1 h, washed, and developed by adding
3,3′,5,5′-tetramethylbenzidine substrate (100 µL/well).
Color was allowed to develop for 4 min, the reaction was
stopped by adding 100 µL of 0.18 mol/L H2SO4 to each
well, and the plates were read at a wavelength of 450 nm. 
Data were analyzed three different ways. In ELISA 1,
the reactivity of each serum specimen to Msg was
expressed as the ratio of reactivity to the pET vector (mean
optical density [OD] Msgtest serum – mean OD PBStest serum) /
(mean OD pETtest serum
__ mean OD PBStest serum). In ELISA
2, the reactivity to Msg was expressed as the percent reac-
tivity to TT for each serum: (mean OD Msgtest serum
__ mean
OD PBStest serum) / (mean OD TTtest serum
__ mean OD PBStest
serum) x 100. In ELISA 3, the reactivity to Msg was
expressed as percent reactivity of the standard serum:
(mean OD Msgtest serum – the mean OD PBStest serum) / mean
OD Msgstandard serum – the mean OD PBSstandard serum) x 100.
Variations in assay results using the control serum were
measured for MsgA and MsgC on a per-plate basis (n = 6,
coefficients of variation [CV] 3%–5%for MsgA and
3.6%–7% for MsgC), a daily basis using two plates (n =
12, CV 3.3%–5.8% for MsgA and 4.8%–7.4% for MsgC),
and an overall basis (across 4 days with two plates per day)
(n = 48, CV 8.7% for Msg A and 13.3% for MsgC).
Statistics
Geometric means and 95% confidence intervals (95%
CI) of observed ELISA measurements were obtained by
patient category and antigen status. Before analysis,
ELISA measurements were log-transformed to approxi-
mate normality. Weighted least squares regression analysis
of variance (ANOVA) was carried out for each ELISA
measurement separately to test the equality of ELISA
means between PCP-positive, PCP-negative, HIV, and
donor categories, adjusted for categorically modeled anti-
gen level (A, B, C). The weighting values were the inverse
of the within-category ELISA variances. The means of
PCP-positive, PCP-negative, and HIV groups were com-
pared to the mean of blood donors by calculating a post
hoc linear contrast of individual estimates. The model
included interactions between antigens and patient cate-
gories to allow for possible differences in the effect of
patient status on mean values of ELISA among antigen
levels. Significance was judged as p < 0.05, unless stated
otherwise. 
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ELISA was investigated by logistic regression in which
Western blot (dichotomous ±) was related to continuously
measured ELISA, adjusted for categorically modeled anti-
gen level (A, B, C) and patient group (PCP-positive, PCP-
negative, HIV, donor). Associations were obtained by
calculating the odds of Western blot positive versus nega-
tive results for increasing ELISA reactivity, ranging from
low (25th percentile) to high (75th percentile). From the
same analysis, odds ratios (ORs) measuring associations
between Western blot positivity and patient status (donor
versus PCP-positive, PCP-negative, HIV) were calculated
at midpoints of ELISA1, 2, and 3, equal to 2.7, 16, and 35,
respectively. ORs for the combined PCPgroups, i.e., blood
donor versus HIV, were obtained by comparing the mean
of PCPgroups to mean of the donor group, calculated from
a linear contrast of the individual group effects.
Significance was judged by obtaining 95% CI of ORs. A
CI that does not include 1 indicates a significant associa-
tion (two-sided p = 0.05) between the odds of Western blot
reactivity when ELISA results are high versus low, or
between blood donors and patient groups at the midpoint
of ELISA measurements. 
Spearman correlation coefficients were obtained by
measuring associations between ELISAand CD4 and viral
counts in HIV patients. All statistical analyses were per-
formed by using the SAS statistical analysis system (SAS
for Windows, Version 8.2, SAS Institute, Cary, NC.)
Results
Analysis of HIV-Positive and 
Blood Donor Serum Specimens 
The reactivity of serum antibodies from HIV patients
and healthy blood donors to MsgA, MsgB, and MsgC was
compared by three different ELISA analyses (Table 1).
Irrespective of the method of analysis, HIV-positive
patients had significantly higher levels of antibody than
healthy blood donors to each of the Msg fragments (p <
0.001), even though the range of ELISAvalues overlapped
between the two groups (Figure). In blood donors, antigen
reactivity was hierarchical (MsgC > MsgA> MsgB) for all
methods of analysis. Similar results were seen for HIV
patients in ELISA 1 and 2, but in ELISA 3 reactivity to
MsgB was higher than to MsgAor MsgC (not significant). 
To determine if the increased reactivity of the HIV
serum samples could be accounted for by increased anti-
bodies in the PCP-positive patients as a consequence of
infection with Pneumocystis, we compared the reactivity
of HIV-positive, PCP-negative and HIV-positive, PCP-
positive patients with that of blood donors (Table 1,
Figure). Irrespective of the ELISA method chosen, the
reactivity of PCP-negative serum samples was higher than
that of blood donor serum samples for each of the Msg
fragments (p < 0.01), indicating that PCP status alone
could not account for the increased antibody reactivity
found in the HIV cohort.
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Table 1. Geometric mean values and 95% CI of ELISA by blood donor, PCP-positive, PCP-negative, and HIV status for each antigen
a 
ELISA  Antigen  Blood donor, n = 95 (95% CI)  PCP+, n = 33 (95% CI)  PCP–, n = 66 (95% CI)  HIV+ (PCP+, PCP–), n = 94 (95% CI) 
A  1.2 (0.8 to 1.8)  6.8 (4.1 to 11.3)  6.0 (4.6 to 7.7)  6.2 (4.9 to 7.9) 
B  1.0 (0.7 to 1.4)  3.7 (2.4 to 5.8)  2.9 (2.3 to 3.6)  3.2 (2.5 to 3.9) 
1 (n = 189) 
C  2.0 (1.2 to 3.1)  13.0 (7.9 to 21.4)  7.5 (6.0 to 9.3)  9.1 (7.3 to 11.4) 
A  9.0 (6.3 to 12.7)  31.2 (22.0 to 44.2)  28.9 (21.2 to 39.5)  29.7 (23.6 to 37.4) 
B  4.2 (2.7 to 6.6)  16.2 (11.5 to 22.7)  15.0 (11.9 to 18.9)  15.4 (12.8 to 18.6) 
2 (n = 189) 
C  21.4 (15.0 to 30.7)  57.8 (48.1 to 69.3)  39.1 (31.7 to 48.2)  44.9 (38.5 to 52.2) 
A  18.6 (10.5 to 32.9)  73.5 (53.0 to 102.1)  73.8 (54.1 to 100.7)  73.7 (58.6 to 92.7) 
B  8.2 (4.0 to 16.6)  102.6 (73.0 to 144.2)  103.8 (83.0 to 129.7)  103.4 (86.1 to 124.2) 
3 (n = 189) 
C  22.1 (12.6 to 38.6)  120.1 (99.8 to 144.5)  81.2 (66.7 to 98.9)  93.2 (80.5 to 107.9) 
aCI, confidence interval; ELISA, enzyme-linked immunosorbent assay; PCP, Pneumocystis pneumonia. 
Figure. Antibody reactivity of healthy blood donors (donors); HIV-
positive; PCP-positive, HIV-positive; and PCP-negative, HIV-pos-
itive patients to human Pneumocystis major surface glycoprotein
C (MsgC) by enzyme-linked immunosorbent assay 1 (ratio to
pET), showing the range, 25% and 75% confidence intervals, and
median of the data. Data were log-transformed to approximate
normality.Comparison of PCP-Negative and 
PCP-Positive Serum Specimens
PCP-positive patients had significantly higher reactivi-
ty to MsgC than PCP-negative patients by all three meth-
ods of analysis (p < 0.05, p < 0.01, and p < 0.01 for ELISA
1, 2, and 3, respectively). Reactivity to MsgAor MsgB did
not significantly differ between the populations by any
method of analysis.
In ELISA 1, MsgC elicited the highest reactivity in
both PCP-positive and PCP-negative groups, which was
significant when compared to reactivity to MsgB (p <
0.001 in both groups) but not to MsgA (p nonsignificant
in both groups). In ELISA 2, the recognition of MsgC by
PCP-positive patients was significantly higher than that of
MsgA or MsgB, and MsgA exhibited higher reactivity
than MsgB (p < 0.01, all comparisons). Similarly, in PCP-
positive patients, the highest reactivity in ELISA 3 was to
MsgC, which was significant when compared to MsgA
(p < 0.01) but not compared to MsgB (p > 0.05). In con-
trast to the other ELISAmethods, the highest levels in the
PCP-negative group were to MsgB, but this finding was
not significant (p > 0.05).  
Correlation between ELISA and Western Blot
To determine whether a correlation existed between
ELISA values and reactivity by Western blot analysis, we
compared data obtained by ELISA with Western blot
results by logistic regression. As demonstrated by the
adjusted ORs and 95% CI, a significant association was
found between seropositivity by Western blot and higher
ELISA values among HIV-positive patients (p < 0.05) but
not among blood donors (Table 2). This association was
found for reactivity to all Msg fragments and all ELISA
methods, with the highest association being found for
ELISA 3. Significant and positive associations were also
found between Western blot reactivity and blood
donor/HIV status at ELISA midpoints (geometric mean
values shown by ELISA) (Table 3). Again, the highest
value was found with ELISA 3.
Tables 2 and 3 show results of logistic regression analy-
ses relating ELISA values and Western blot reactivity in
PCP-positive and PCP-negative patients. A significant
association was found between increasing ELISA 1 values
and Western blot seropositivity in PCP-positive patients
only (p < 0.05). Similar results were found for each Msg
fragment in each patient group. Also, a significant associ-
ation between increasing ELISA 2 levels and Western blot
positivity in PCP-positive patients was found (p < 0.05).
The relationship between ELISA 2 measurements and
Western blot reactivity varied by Msg fragment in PCP-
negative patients; a significant association was found for
Msg C only (p < 0.05, OR = 16.9, 95% CI = 3.6 to 79.7).
For ELISA 3, a significant OR was found for both patient
groups (p < 0.05). Significant and positive associations
were also found between Western blot reactivity and blood
PCP status at ELISAmidpoints (geometric mean values of
ELISA) (Table 3), with the highest value found for ELISA
3. Spearman correlations were obtained between ELISA
values and CD4+ cell counts or viral titer in PCP-positive
and PCP-negative patients. No significant associations
were noted (data not shown). 
In our earlier study, PCP developed in 9 of the 61 PCP-
negative patients after their serum samples had been
obtained. None of these persons showed antibodies to
MsgC by Western blot. These patients had a geometric
mean antibody level in ELISA 1 o f 5.47 (95% CI 2.57 to
11.64) compared with a level of 7.88 (95% CI 6.25 to 9.94)
in the 52 PCP-negative patients. Although mean serum
levels were not significantly different among patient
groups (p > 0.05), some trends were interesting. Patients in
whom PCP developed subsequent to collecting their spec-
imens had lower antibody levels to MsgC than the other
patient groups. 
Discussion
Using ELISA, we have compared blood donor and
HIV-positive patient serum samples for antibody reactivi-
ty to recombinant fragments of P. jiroveci Msg. We ana-
lyzed the data by three independent methods and found
that HIV-positive patients had significantly higher mean
serum antibody levels to MsgA, MsgB, and MsgC than
healthy blood donors by all methods of analysis.
Furthermore, when the HIV-positive patients were separat-
ed on the basis of a prior documented episode of PCP, the
PCP-positive patients had higher antibody levels to MsgC
than the PCP-negative patients by all ELISAmethods test-
ed. These results differ from published work (25,26) show-
ing no difference in antibody levels between HIV-positive,
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Table 2. Adjusted odds ratios (95% CI) measuring the associations between Western blot reactivity and ELISA values (25–75 
percentile increase) among 189 study participants
a,b 
ELISA  Blood donor, n = 95 (95% CI)  PCP+, n = 33 (95% CI)  PCP–, n = 61 (95% CI)  HIV, n = 94 (95% CI) 
1  1.1 (0.9 to 1.4)  5.1 (2.2 to 11.8)  1.4 (0.8 to 2.6)  2.7 (1.2 to 5.8) 
2  1.1 (0.9 to 1.4)  20.4 (6.4 to 65.1)  3.6 (2.0 to 6.6)  8.6 (4.4 to 16.9) 
3  1.0 (0.9 to 1.1)  11.6 (3.6 to 37.9)  7.4 (3.6 to 15.1)  9.3 (4.7 to 18.5) 
aCI, confidence interval; ELISA, enzyme-linked immunosorbent assay; PCP, Pneumocystis pneumonia. 
bOdds ratios were obtained by using logistic regression. Positive associations were found between Western blot reactivity and increasing ELISA. Based on 95% 
confidence intervals, the odds of Western blot reactivity were significantly related (p < 0.05) to increasing ELISA 1, 2, and 3 among PCP+ patients and HIV patients 
across all antigens. For PCP– patients this result was true for ELISA 2 and 3 only. No significant results were found for the blood donor group. PCP-positive patients; HIV-positive, PCP-negative
patients; and healthy controls to recombinant fragments of
Msg. The discrepancy in results could be due to differ-
ences in study populations, Msg preparations, and methods
(28).
At the onset of the study, we decided on three independ-
ent methods of analysis of the data in an attempt to stan-
dardize the assay. Each method of analysis provides
different information about the results of the ELISA, and
each method has strengths and weaknesses. The first analy-
sis involved comparing the response to recombinant Msg
fragments with the response to protein expressed from the
pET vector without insert. The protein expressed from the
sequences of the pET vector is an integral part of each Msg
recombinant tested, and therefore this method of analysis
allows measurement of Msg-specific immune reactivity
corrected internally for any reactivity to the vector-derived
sequences. The second method of analysis was a compari-
son of the reactivity to Msg with that of a standard antigen,
tetanus toxoid, chosen because it is likely that most adults
have been vaccinated against tetanus toxoid and are likely
to react with this protein in assay. While this method is con-
sistent when analyzing individual serum samples, one
potential problem with this analysis is that the antibody
response to tetanus toxoid varies from person to person.
This variation means that, when a population is studied, the
range of values obtained by this method can be quite large.
The third method of analysis was comparing the test serum
reactivity to that of a standard serum. Our standard serum
was chosen because of clear reactivity to all Msg fragments
tested in Western blot analysis. However, this serum
responded weakly to MsgB in ELISA. Our choice of stan-
dard serum is still valid and is useful for comparing the
reactivity to any one of the fragments in different popula-
tions. However, the use of this method to compare respons-
es to different Msg fragments must be treated with caution.
An alternative approach would be to use a pool of serum
samples from several donors chosen for reactivity to the
individual Msg fragments.
We have previously shown that MsgB was the most
common fragment recognized by blood donors and HIV
patients (27), and a significant difference was found in the
frequency of recognition of MsgB between donors and
HIV-positive patients. In contrast to these results, this
study has shown that MsgC is the antigen with the highest
level of reactivity in both the healthy and HIV-positive
populations tested. This apparent discrepancy between
assays is probably due to the nature of the epitopes recog-
nized in the different assays, since the recombinant anti-
gens were reduced and denatured during testing by
Western blot analysis but not in ELISA. The lack of strict
concordance in recognition of Msg fragments in ELISA
and Western blot has also been seen by other groups
(15,26) However, we did find a significant association
between ELISAantibodies and Western blot seropositivity
in HIV-positive patients but not in blood donors. Using
regression analysis, we calculated ORs measuring the
association of Western blot positivity and study participant
(blood donor vs. HIV) status at the midpoint of each
ELISA. These results showed a significantly greater likeli-
hood of being Western blot–positive among blood donors
than HIV patients. These data can be explained by several
factors. First, 84% of our blood donors, but only 66% of
the HIV patients (p = 0.003), responded to at least one of
the three Msg fragments. Second, blood donors have con-
sistently lower ELISA values than HIV patients. Third,
blood donors exhibit larger standard deviations than HIV
patients in their ELISA values, suggesting they have a
more heterogeneous antibody response in terms of affinity
for Msg epitopes. The association between Western blot
positivity and ELISA values is probably not due to the
PCP-positive patients’ response, as PCP-negative patients
also showed an association in two of the three ELISA
methods.
Despite their lower Western blot seropositivity rate,
HIV patients had significantly higher mean serum anti-
body levels to MsgA, MsgB, and MsgC than healthy blood
donors by both methods of ELISAanalysis. That HIV-pos-
itive patients should have higher levels of antigen-specific
reactivity than healthy blood donors is surprising. One
possible explanation is that HIV-positive patients may
come into contact with Pneumocystis more frequently or
for longer periods of time before the organism is cleared
from the lungs (1). While this exposure to Pneumocystis
may not result in overt PCP, the immune system likely
takes longer to clear the organisms from the lung, allowing
responses to new or subdominant epitopes to develop. In
contrast, these responses would be absent or diminished in
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Table 3. Adjusted odds ratios (95% CI) measuring the associations between Western blot reactivity and participant status (blood donor 
versus PCP-positive, PCP-negative, HIV) among 189 study participants
a,b 
ELISA  Midpoint  Blood donor: PCP+ (95% CI)  Blood donor: PCP– (95% CI)  Blood donor: HIV (95% CI) 
1  2.7  3.2 (1.6 to 6.7)  2.2 (1.4 to 3.5)  2.7 (1.7 to 4.3) 
2  16  5.9 (2.5 to 14.3)  3.2 (2.0 to 5.3)  4.3 (2.6 to 7.4) 
3  35  10.0 (2.9 to 33.3)  9.1 (4.4 to 20.0)  9.4 (4.6 to 19.3) 
aCI, confidence interval; ELISA, enzyme-linked immunosorbent assay; PCP, Pneumocystis pneumonia. 
bOdds ratios measuring the association between Western blot reactivity and participant status were calculated at the midpoints of ELISA measurements over all antigens. 
Based on 95% confidence intervals, blood donors had significantly increased odds of Western blot reactivity compared to each patient group (p < 0.05) for each ELISA. 
 healthy populations, who would clear Pneumocystis from
the lungs more quickly. Therefore, the higher response in
HIV-positive patients could be due to the accumulated
responses to multiple epitopes, whereas the responses in
healthy blood donors may be limited to immunodominant
epitopes. An alternative explanation may be that the ele-
vated levels of reactivity seen in HIV-positive serum are
specific for the IgG isotypes and that the elevated levels of
the isotype profile of Msg-specific antibodies may be
skewed in healthy persons and HIV-positive patients.
This study shows that PCP-positive patients have high-
er antibodies to MsgC than PCP-negative patients by all
ELISA methods. Furthermore, nine HIV patients in whom
PCP developed after their serum specimens had been
obtained and who did not have antibodies to MsgC by
Western blot (27) had lower levels of antibodies to MsgC
in this study. Overall, a hierarchy appeared to exist in the
level of serum antibodies to MsgC by ELISA: highest in
PCP-positive patients, next highest in PCP-negative
patients, and lowest in blood donors. 
Humoral immunity has long been thought to have little
role in host defenses against Pneumocystis because PCP
develops in many patients despite preexisting antibodies to
the organism (8). Yet considerable evidence, mainly from
animal models, now suggests that B cells contribute to
these host defenses (2). Also of interest is that some sero-
logic studies have shown decreased antibody levels or pro-
duction before a person acquires PCP or increased
antibody levels after a patient recovers from PCP
(6,8,23,29–34). Our data suggest that analysis of the
immune reactivity to Msg fragments, MsgC in particular,
may be important in understanding differences between
patient populations and may lead to identifying epitopes
linked to protection from or susceptibility to PCP in popu-
lations at risk.
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